vs

Side-by-side financial comparison of Editas Medicine, Inc. (EDIT) and Ispire Technology Inc. (ISPR). Click either name above to swap in a different company.

Editas Medicine, Inc. is the larger business by last-quarter revenue ($24.7M vs $20.3M, roughly 1.2× Ispire Technology Inc.). Editas Medicine, Inc. runs the higher net margin — -22.7% vs -32.5%, a 9.8% gap on every dollar of revenue. On growth, Editas Medicine, Inc. posted the faster year-over-year revenue change (-19.2% vs -51.5%). Ispire Technology Inc. produced more free cash flow last quarter ($-4.0M vs $-36.4M). Over the past eight quarters, Editas Medicine, Inc.'s revenue compounded faster (366.9% CAGR vs -17.8%).

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Ispire Technology Inc. is a global tech firm specializing in R&D, manufacturing and sales of advanced vaporization hardware and supporting consumables. It serves nicotine and legal cannabis consumer markets, operates two core segments of hardware and branded cannabis products, covers North America, Europe and Asia-Pacific, delivering compliant innovative vapor solutions for B2B partners and end users.

EDIT vs ISPR — Head-to-Head

Bigger by revenue
EDIT
EDIT
1.2× larger
EDIT
$24.7M
$20.3M
ISPR
Growing faster (revenue YoY)
EDIT
EDIT
+32.3% gap
EDIT
-19.2%
-51.5%
ISPR
Higher net margin
EDIT
EDIT
9.8% more per $
EDIT
-22.7%
-32.5%
ISPR
More free cash flow
ISPR
ISPR
$32.4M more FCF
ISPR
$-4.0M
$-36.4M
EDIT
Faster 2-yr revenue CAGR
EDIT
EDIT
Annualised
EDIT
366.9%
-17.8%
ISPR

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
EDIT
EDIT
ISPR
ISPR
Revenue
$24.7M
$20.3M
Net Profit
$-5.6M
$-6.6M
Gross Margin
17.1%
Operating Margin
-31.3%
-33.9%
Net Margin
-22.7%
-32.5%
Revenue YoY
-19.2%
-51.5%
Net Profit YoY
87.6%
17.4%
EPS (diluted)
$0.03
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EDIT
EDIT
ISPR
ISPR
Q4 25
$24.7M
$20.3M
Q3 25
$7.5M
$30.4M
Q2 25
$3.6M
$20.1M
Q1 25
$4.7M
$26.2M
Q4 24
$30.6M
$41.8M
Q3 24
$61.0K
$39.3M
Q2 24
$513.0K
$37.3M
Q1 24
$1.1M
$30.0M
Net Profit
EDIT
EDIT
ISPR
ISPR
Q4 25
$-5.6M
$-6.6M
Q3 25
$-25.1M
$-3.3M
Q2 25
$-53.2M
$-14.8M
Q1 25
$-76.1M
$-10.9M
Q4 24
$-45.4M
$-8.0M
Q3 24
$-62.1M
$-5.6M
Q2 24
$-67.6M
$-3.5M
Q1 24
$-62.0M
$-5.9M
Gross Margin
EDIT
EDIT
ISPR
ISPR
Q4 25
17.1%
Q3 25
17.0%
Q2 25
12.3%
Q1 25
18.2%
Q4 24
18.5%
Q3 24
19.5%
Q2 24
28.3%
Q1 24
20.4%
Operating Margin
EDIT
EDIT
ISPR
ISPR
Q4 25
-31.3%
-33.9%
Q3 25
-325.4%
-8.9%
Q2 25
-1440.6%
-72.7%
Q1 25
-1635.1%
-40.4%
Q4 24
-152.2%
-17.6%
Q3 24
-107649.2%
-13.4%
Q2 24
-14016.2%
-9.2%
Q1 24
-5902.3%
-18.8%
Net Margin
EDIT
EDIT
ISPR
ISPR
Q4 25
-22.7%
-32.5%
Q3 25
-333.0%
-10.7%
Q2 25
-1487.8%
-73.4%
Q1 25
-1633.5%
-41.5%
Q4 24
-148.3%
-19.1%
Q3 24
-101870.5%
-14.2%
Q2 24
-13178.8%
-9.4%
Q1 24
-5458.1%
-19.7%
EPS (diluted)
EDIT
EDIT
ISPR
ISPR
Q4 25
$0.03
$-0.12
Q3 25
$-0.28
$-0.06
Q2 25
$-0.63
$-0.26
Q1 25
$-0.92
$-0.19
Q4 24
$-0.55
$-0.14
Q3 24
$-0.75
$-0.10
Q2 24
$-0.82
$-0.07
Q1 24
$-0.76
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EDIT
EDIT
ISPR
ISPR
Cash + ST InvestmentsLiquidity on hand
$146.6M
$17.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$27.3M
$-7.7M
Total Assets
$186.5M
$84.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EDIT
EDIT
ISPR
ISPR
Q4 25
$146.6M
$17.6M
Q3 25
$165.6M
$22.7M
Q2 25
$178.5M
$24.4M
Q1 25
$221.0M
$23.5M
Q4 24
$269.9M
$34.4M
Q3 24
$265.1M
$37.7M
Q2 24
$279.1M
$35.1M
Q1 24
$296.2M
$39.5M
Total Debt
EDIT
EDIT
ISPR
ISPR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$57.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
EDIT
EDIT
ISPR
ISPR
Q4 25
$27.3M
$-7.7M
Q3 25
$13.5M
$-1.8M
Q2 25
$19.2M
$604.7K
Q1 25
$62.4M
$14.8M
Q4 24
$134.3M
$24.2M
Q3 24
$175.6M
$30.7M
Q2 24
$232.0M
$34.5M
Q1 24
$294.4M
$35.9M
Total Assets
EDIT
EDIT
ISPR
ISPR
Q4 25
$186.5M
$84.4M
Q3 25
$201.8M
$96.4M
Q2 25
$210.6M
$102.2M
Q1 25
$263.7M
$115.7M
Q4 24
$341.6M
$132.0M
Q3 24
$327.6M
$129.0M
Q2 24
$384.8M
$122.6M
Q1 24
$440.3M
$108.0M
Debt / Equity
EDIT
EDIT
ISPR
ISPR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.43×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EDIT
EDIT
ISPR
ISPR
Operating Cash FlowLast quarter
$-36.4M
$-4.0M
Free Cash FlowOCF − Capex
$-36.4M
$-4.0M
FCF MarginFCF / Revenue
-147.3%
-19.9%
Capex IntensityCapex / Revenue
0.2%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-14.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EDIT
EDIT
ISPR
ISPR
Q4 25
$-36.4M
$-4.0M
Q3 25
$-30.8M
$-1.2M
Q2 25
$-50.2M
$4.7M
Q1 25
$-47.8M
$-12.5M
Q4 24
$-50.8M
$-3.2M
Q3 24
$-52.6M
$3.6M
Q2 24
$-57.1M
$-1.4M
Q1 24
$-49.9M
$3.4M
Free Cash Flow
EDIT
EDIT
ISPR
ISPR
Q4 25
$-36.4M
$-4.0M
Q3 25
$-31.3M
$-1.2M
Q2 25
$3.7M
Q1 25
$-47.9M
$-12.7M
Q4 24
$-51.3M
$-3.2M
Q3 24
$-55.5M
$3.3M
Q2 24
$-60.6M
$-2.2M
Q1 24
$-51.7M
$3.3M
FCF Margin
EDIT
EDIT
ISPR
ISPR
Q4 25
-147.3%
-19.9%
Q3 25
-414.6%
-3.9%
Q2 25
18.6%
Q1 25
-1028.6%
-48.4%
Q4 24
-167.6%
-7.7%
Q3 24
-90998.4%
8.5%
Q2 24
-11804.3%
-5.9%
Q1 24
-4558.9%
10.9%
Capex Intensity
EDIT
EDIT
ISPR
ISPR
Q4 25
0.2%
0.3%
Q3 25
5.7%
0.0%
Q2 25
0.0%
4.8%
Q1 25
2.4%
0.7%
Q4 24
1.8%
0.1%
Q3 24
4788.5%
0.7%
Q2 24
681.1%
2.0%
Q1 24
164.8%
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons